Wall Street brokerages forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce ($1.18) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.18) to ($1.17). Atara Biotherapeutics posted earnings per share of ($1.02) during the same quarter last year, which indicates a negative year over year growth rate of 15.7%. The company is scheduled to announce its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts forecast that the business will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17).
Several equities analysts have issued reports on the company. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Canaccord Genuity restated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, May 8th. Finally, ValuEngine upgraded shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Three research analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Atara Biotherapeutics has a consensus rating of “Hold” and an average target price of $43.17.
In related news, Director Matthew K. Fust sold 12,286 shares of the stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $43.57, for a total value of $535,301.02. Following the transaction, the director now directly owns 19,820 shares in the company, valued at $863,557.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $37.43, for a total transaction of $291,954.00. Following the completion of the transaction, the chief executive officer now owns 812,613 shares in the company, valued at $30,416,104.59. The disclosure for this sale can be found here. In the last 90 days, insiders sold 169,400 shares of company stock worth $7,301,767. 10.60% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in Atara Biotherapeutics by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 129,237 shares of the biotechnology company’s stock valued at $2,339,000 after acquiring an additional 5,415 shares during the last quarter. Geode Capital Management LLC increased its holdings in Atara Biotherapeutics by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 196,841 shares of the biotechnology company’s stock valued at $3,562,000 after buying an additional 4,731 shares during the period. Deutsche Bank AG increased its holdings in Atara Biotherapeutics by 178.5% in the 4th quarter. Deutsche Bank AG now owns 71,085 shares of the biotechnology company’s stock valued at $1,285,000 after buying an additional 45,565 shares during the period. California State Teachers Retirement System increased its holdings in Atara Biotherapeutics by 4.6% in the 4th quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 1,836 shares during the period. Finally, Raymond James & Associates increased its holdings in Atara Biotherapeutics by 7.3% in the 4th quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock valued at $458,000 after buying an additional 1,719 shares during the period. Institutional investors and hedge funds own 98.58% of the company’s stock.
Shares of Atara Biotherapeutics traded up $0.65, hitting $38.10, on Friday, Marketbeat reports. The stock had a trading volume of 229,898 shares, compared to its average volume of 436,390. Atara Biotherapeutics has a 52-week low of $12.65 and a 52-week high of $54.45. The company has a market capitalization of $1.70 billion, a P/E ratio of -9.53 and a beta of 2.55.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
See Also: What does earnings per share mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.